PBYI Q4 2019 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$63M-11.5% YoY

Gross Profit

$53M83.9% margin

Operating Income

-$9M-13.9% margin

Net Income

-$11M-17.8% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+11.6%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$1M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$235M

Total Liabilities

$217M

Stockholders' Equity

$17M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$63M	$71M	-11.5%
Gross Profit	$53M	$61M	-13.2%
Operating Income	-$9M	-$19M	+53.1%
Net Income	-$11M	-$31M	+63.5%

Revenue Segments

Product

$59M93%

License

$4M6%

Royalty

$216,0000%